Comparative Pharmacology
Head-to-head clinical analysis: BESIVANCE versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESIVANCE versus OPTOMYCIN.
BESIVANCE vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESIVANCE is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and leading to bacterial cell death.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
One drop instilled into the affected eye(s) three times daily for 7 days.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Terminal half-life of approximately 1.5-2 hours in adults; prolongation in renal impairment.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 20-30%); biliary excretion contributes to fecal elimination.
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination